Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25253965 | 1.00 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL25344862 | 1.00 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28501706 | 0.98 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18173574 | 0.89 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9447837 | 0.89 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8958401 | 0.89 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8958557 | 0.89 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8958237 | 0.89 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8958406 | 0.86 | SMN1; SMN2 (0.48) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL20696333 | 0.83 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812631-A | Fibroblast activator protein ligand for targeted delivery applications | 菲洛谢姆股份公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115335370-B | Fibroblast activator protein ligand for targeted delivery applications | 菲洛谢姆股份公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | MEN1 823/4885KMT2A 583/4885SMN1; SMN2 143/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | MEN1 823/4885KMT2A 583/4885SMN1; SMN2 143/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | MEN1 823/4885KMT2A 583/4885SMN1; SMN2 143/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.